Nika Pharmaceuticals, Inc. (NIKA) Progress Update

Rhea-AI Summary

Nika Pharmaceuticals (OTCQB: NIKA) provided a progress update on Dec 3, 2025. CEO Dimitar Savov discussed 2026 plans on a podcast and said 2026 will be a crucial year.

Nika Europe is finalizing the technical project for a pharmaceutical factory described as a "building within a building," with construction expected to start soon and factory completion targeted by the end of Q1 2026.

The production line equipment has $387,088 paid and is in final testing before shipment. Management noted technical planning took longer than expected and disclosed major component costs: the water for injections system near $500,000 pre-tax and the advanced HVAC system over $1.1 million pre-tax.

Positive

• Factory completion targeted by end of Q1 2026
• Production equipment $387,088 already paid and in final testing
• Technical project finalized by Nika Europe enabling imminent construction

Negative

• Technical project took longer than initially expected
• Major pre-tax component costs: WFI ~$500,000 and HVAC >$1.1M

HENDERSON, Nev., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) appeared on The Street Reports podcast where CEO Dimitar Savov shared the progress the company has made thus far and outlined what is expected for 2026, which will be a crucial year for the company. You may listen to the podcast episode here.

Additionally, NIKA’s partner, Nika Europe, is finalizing the technical project for the pharmaceutical factory and expects to begin construction soon. Given that the factory is a “building within a building”, the build up time will be short and the factory is expected to be completed by the end of Q1, 2026. The production line equipment, for which $387,088 has already been paid, is in the final testing stages before it can be shipped for installation in the factory.

“Although the technical project has taken a bit longer to complete than initially expected, that is normal due to the myriads of technical details required to build a state-of-the-art pharmaceutical factory adhering to all GMP standards” explained Savov. “To explain the complexity in simple numerical terms, just the water for injections (WFI) system will cost nearly $ 500,000 pre-tax with the advanced HVAC system costing more than $ 1.1 million pre-tax,” continued Savov. “With the launch of the factory, NIKA will develop into a strong pharmaceutical project, bringing significant value to its shareholders,” concluded Savov.

About Nika Pharmaceuticals, Inc.

Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.

Forward-looking Statement:

This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “estimates,” “projects,” “intends,” “plan,” “can,” “will,” “would,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

CONTACT Clifford Redekop, Secretary
COMPANY Nika Pharmaceuticals, Inc.
PHONE (702)-326-3615
EMAIL info@nikapharmaceuticals.com
WEB www.nikapharmaceuticals.com

FAQ

When does Nika Pharmaceuticals (NIKA) expect the new factory to be completed?

Management expects the factory to be completed by the end of Q1 2026.

How much has Nika paid toward production line equipment for the NIKA factory?

The company has paid $387,088 for production line equipment, which is in final testing.

What are the major equipment costs disclosed by Nika for the factory?

Company disclosed the WFI system will cost nearly $500,000 pre-tax and the HVAC more than $1.1 million pre-tax.

Did Nika management report any delays to the factory project timeline?

Management said the technical project took a bit longer than expected but described this as normal for complex GMP facility planning.

Where did CEO Dimitar Savov outline NIKA's 2026 expectations?

CEO Dimitar Savov discussed company progress and 2026 expectations on The Street Reports podcast on Dec 3, 2025.